XWELL, Inc.
For the period ended Nov 14, 2025. Filed Nov 14, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Nov 14, 2025 · Filed Nov 14, 2025
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Biosecurity Program
Biosecurity Program
Through XpresCheck, XWELL operates at the forefront of global biosecurity.
In March 2025, XWELL secured a three-year extension of its Traveler-based Genomic Surveillance Program (“TGS”), operated with the CDC and Ginkgo Bioworks Holdings. The TGS program, provides early detection of emerging pathogens, safeguarding national health through airport-based biosurveillance.
3
PRESS RELEASE
Building on this foundation, XWELL’s biosecurity platform and expertise position the Company to capture new international growth opportunities across travel and mass-gathering settings. This includes biosecurity at large-scale deployments at high-profile global events such as the 2026 World Cup, the Haj, the 2026 Winter Olympics in Italy and the 2028 Summer Olympics in Los Angeles.
XpresCheck, which helped power national COVID-19 testing and reporting during the pandemic, now serves as the operational and technological core of this next phase of XWELL’s strategic, science-driven wellness initiatives.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.